S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% BITCOIN 64,633.45 -0.25%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% BITCOIN 64,633.45 -0.25%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

UTHR

United Therapeutics Corporation NMS · UTHR

$535.67 +6.62 (+1.25%)

Pullback · -0.56σ Grade C

+ Compare Open in Sniper

News · UTHR

Full news feed →

Big Pharma Has a Case of Merger Mania

The Motley Fool · 19d ago

iShares U.S. Pharmaceuticals ETF Tops Simplify Health Care ETF Returns

The Motley Fool · 38d ago

These 3 Stocks Lowered Their Share Counts Drastically in Q1

Investing.com · 39d ago

Pulmonary Arterial Hypertension Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

GlobeNewswire Inc. · 60d ago

Transplants.org Launches as Centralized Education and Navigation Platform for Organ and Stem Cell Transplant Patients

GlobeNewswire Inc. · 74d ago

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

GlobeNewswire Inc. · 101d ago

Stocks Rise As Powell's Remarks Cool Rate Fears: What's Moving Markets Monday?

Benzinga · 110d ago

Why Is United Therapeutics Stock Soaring Monday?

Benzinga · 110d ago

United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening

Benzinga · 138d ago

United Therapeutics Reports Early Success For External Liver Support In Acute Failure

Benzinga · 173d ago

MannKind Provides Business Updates and 2026 Growth Drivers

Benzinga · 191d ago

Why a $27 Million Buy Signals New Confidence in Weatherford Stock

The Motley Fool · 221d ago

Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?

The Motley Fool · 221d ago

Nepsis Liquidates $14 Million CyberArk Software (NASDAQ: CYBR) Position: Did the Stock Soar Too High, Too Fast?

The Motley Fool · 265d ago

Artificial Lung Market to Grow at 10.84% CAGR, Hits USD 7.05 Bn by 2034

GlobeNewswire Inc. · 274d ago

3 High-Growth Stocks Poised to Extend Gains Into Year-End

Investing.com · 310d ago

MannKind (MNKD) Q2 Revenue Rises 6%

The Motley Fool · 346d ago

ROSEN, A LEADING LAW FIRM, Encourages 3D Systems Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - DDD

GlobeNewswire Inc. · 355d ago

AppLovin, Chewy And Carvana Are Among Top 11 Large Cap Losers Last Week (June 9-13): Are The Others In Your Portfolio?

Benzinga · 398d ago

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

GlobeNewswire Inc. · 421d ago

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

GlobeNewswire Inc. · 432d ago

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

GlobeNewswire Inc. · 442d ago

Market Turbulence? These 20 Stocks Boast a Perfect Piotroski Score and 40%+ Upside

Investing.com · 485d ago

Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight

GlobeNewswire Inc. · 550d ago

Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?

Zacks Investment Research · 711d ago